Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-nasal Sufentanil for Analgesia of Vaso-occlusive Crisis in Sickle-cell Adults
NCT04076748Phase 3Terminated
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of sufentanil in sickle cell disease (SCD), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Jul 2021; status: terminated.
02
Drugs
sufentanil
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04076748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04076748.